The European medicines regulator said that a higher rate of death and disease complications in recent trials meant the ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Patients with sickle cell disease and beta-thalassemia treated with exagamglogene autotemcel reported substantial and ...

Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...

Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of ...

A one-time gene-editing therapy, exagamglogene autotemcel (exa-cel), has demonstrated sustained and clinically meaningful ...

In a 2025 qualitative analysis of payer insights conducted by McKesson and Lumanity, 20 payers representing nearly 280 million covered lives reported that although they broadly view CGTs as safe (90%) ...

Beam Therapeutics, Inc. (($BEAM)) announced an update on their ongoing clinical study. Beam Therapeutics, Inc. is conducting the BEACON trial, ...

Fulcrum Therapeutics (($FULC)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for Fulcrum ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. It's a blow to the SCD ...

A Phase 1b clinical trial testing pociredir in adults with sickle cell disease has completed enrollment of its high-dose ...

In the fall of my sophomore year of high school, my hematologist recommended me for my pediatric sickle cell program’s teen clinic. At that point, I was going to the doctor every one to three months, ...